🟢 GH Research is trading 5% up today after narrower-than-expected loss, Phase 3-ready FDA feedback

GH Research is trading 5.46% up at $30.72 after reporting a second-quarter loss of $0.23 per share, narrower than the $0.31 consensus estimate.

• FDA feedback indicated its CMC and device plans appear Phase 3 ready; pivotal-trial initiation remains targeted in 2026.
• Cash, equivalents, and marketable securities totaled $362.7 million at June 30, supporting execution.
• Despite slightly weaker major U.S. indexes and a broader biotech rally, the earnings and development update is the clearest catalyst.